Cargando…

Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study

Levodopa-carbidopa intestinal gel (LCIG) is a method of continuous administration of levodopa – the standard treatment in Parkinson disease (PD, a neurodegenerative disorder characterized by resting tremor, rigidity, gait impairment, and bradykinesia), thought to reduce the short-life and pulsatile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popa, Luminita C., Leucuta, Daniel-Corneliu, Tohanean, Nicoleta, Popa, Stefan-Lucian, Perju-Dumbrava, Lacramioara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	5300
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668461/ https://www.ncbi.nlm.nih.gov/pubmed/33181715 http://dx.doi.org/10.1097/MD.0000000000023249

Ejemplares similares

Artificial intelligence applications and robotic systems in Parkinson's disease (Review)
por: Perju-Dumbrava, Lacramioara, et al.
Publicado: (2022)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2017)

Large-Fiber Neuropathy in Parkinson’s Disease: Clinical, Biological, and Electroneurographic Assessment of a Romanian Cohort
por: Vanta, Oana Maria, et al.
Publicado: (2019)

Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis
por: Wang, Yan, et al.
Publicado: (2021)

Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single‐center long‐term follow‐up study
por: Rus, Tomaž, et al.
Publicado: (2022)

Life-threatening complications of hyperemesis gravidarum
por: Popa, Stefan L., et al.
Publicado: (2021)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

Nursing procedures for advanced dementia: Traditional techniques versus autonomous robotic applications (Review)
por: David, Liliana, et al.
Publicado: (2022)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Levodopa reverse stridor and prevent subsequent endotracheal intubation in Parkinson disease patients with bilateral vocal cord palsy: A case report
por: Tsai, Chia-Chan, et al.
Publicado: (2016)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson’s disease: Results from a single-center trial
por: Su, Dan, et al.
Publicado: (2023)

Addition of Tolcapone in Intrajejunal Levodopa Infusion Therapy Requires a Pronounced Dose Reduction
por: Schröter, Nils, et al.
Publicado: (2020)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa
por: Haraszti, Samantha, et al.
Publicado: (2018)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
por: GÜLTEKİN, Murat, et al.
Publicado: (2020)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
por: Pauls, K. Amande M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i0jshrtn0lg9c5k5d92as6fpr5